PRVB
Provention Bio Inc
A biopharmaceutical company built to prevent and intercept immune-system diseases before they fully take hold, Provention Bio is best known for TZIELD (teplizumab), the first therapy approved to delay the onset of type 1 diabetes in at-risk patients. Its name is a mash-up of "prevention" and "interception," reflecting the company's core mission. Co-founded by Ashleigh Palmer and Dr. Francisco Leon, it was acquired by the global drugmaker Sanofi in 2023.
CUSIP: 74374N102HealthcareUS1 holder